Forbion portfolio company, Enterprise Therapeutics, was featured in a Fierce Biotech article following positive Phase 2 results for its inhaled ENaC inhibitor ETD001 in cystic fibrosis. The study met its primary endpoint, demonstrating a statistically significant improvement in lung function in patients ineligible for CFTR modulators, an area of high unmet need. The article highlights Enterprise’s progress in advancing a differentiated approach in a field where several large pharma companies have previously struggled.